Back to Search
Start Over
A phase II study of pembrolizumab and paclitaxel in refractory extensive disease small cell lung cancer
- Source :
- Journal of Clinical Oncology. 36:8575-8575
- Publication Year :
- 2018
- Publisher :
- American Society of Clinical Oncology (ASCO), 2018.
-
Abstract
- 8575Background: Patients with platinum refractory extensive disease (ED) small cell lung cancer (SCLC) have a poor prognosis and a little progress have been made. We aimed to investigate the effica...
- Subjects :
- 0301 basic medicine
Oncology
Cancer Research
medicine.medical_specialty
Poor prognosis
Extensive Disease
business.industry
Phases of clinical research
Pembrolizumab
respiratory tract diseases
03 medical and health sciences
chemistry.chemical_compound
030104 developmental biology
0302 clinical medicine
Paclitaxel
chemistry
Refractory
030220 oncology & carcinogenesis
Platinum resistance
Internal medicine
Medicine
Non small cell
business
Subjects
Details
- ISSN :
- 15277755 and 0732183X
- Volume :
- 36
- Database :
- OpenAIRE
- Journal :
- Journal of Clinical Oncology
- Accession number :
- edsair.doi...........f0c67baaad31a00032e36655c4277221